Ocular Therapeutix, Inc. (OCUL)
10.64
-0.26
(-2.43%)
USD |
NASDAQ |
Sep 03, 16:00
10.64
0.00 (0.00%)
After-Hours: 20:00
Ocular Therapeutix Research and Development Expense (TTM) : 223.51M for June 30, 2026
Research and Development Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 223.51M |
| March 31, 2026 | 220.45M |
| December 31, 2025 | 197.10M |
| September 30, 2025 | 187.28M |
| June 30, 2025 | 171.98M |
| March 31, 2025 | 149.76M |
| December 31, 2024 | 127.64M |
| September 30, 2024 | 102.84M |
| June 30, 2024 | 80.81M |
| March 31, 2024 | 67.04M |
| December 31, 2023 | 61.06M |
| September 30, 2023 | 58.40M |
| June 30, 2023 | 57.10M |
| March 31, 2023 | 55.11M |
| December 31, 2022 | 53.46M |
| September 30, 2022 | 52.50M |
| June 30, 2022 | 51.50M |
| March 31, 2022 | 52.26M |
| December 31, 2021 | 50.08M |
| September 30, 2021 | 45.13M |
| June 30, 2021 | 39.36M |
| March 31, 2021 | 33.52M |
| December 31, 2020 | 28.69M |
| September 30, 2020 | 31.20M |
| June 30, 2020 | 34.48M |
| Date | Value |
|---|---|
| March 31, 2020 | 35.87M |
| December 31, 2019 | 41.09M |
| September 30, 2019 | 41.22M |
| June 30, 2019 | 40.67M |
| March 31, 2019 | 40.00M |
| December 31, 2018 | 36.92M |
| September 30, 2018 | 34.56M |
| June 30, 2018 | 32.32M |
| March 31, 2018 | 31.69M |
| December 31, 2017 | 30.19M |
| September 30, 2017 | 29.61M |
| June 30, 2017 | 27.86M |
| March 31, 2017 | 26.72M |
| December 31, 2016 | 27.00M |
| September 30, 2016 | 26.55M |
| June 30, 2016 | 29.07M |
| March 31, 2016 | 28.64M |
| December 31, 2015 | 26.19M |
| September 30, 2015 | 24.28M |
| June 30, 2015 | 20.57M |
| March 31, 2015 | 18.15M |
| December 31, 2014 | 18.47M |
| September 30, 2014 | 15.80M |
| June 30, 2014 | 13.71M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| EyePoint, Inc. | 262.73M |
| LENZ Therapeutics, Inc. | 3.791M |
| Merck & Co., Inc. | 27.26B |
| Theravance Biopharma, Inc. | 24.46M |
| ANI Pharmaceuticals, Inc. | 49.91M |